NEPTUNUS(SZ:000078) Zhong Guo Zheng Quan Bao·2025-12-02 08:31Group 1 - The pharmaceutical commercial sector showed strong performance, with Haiwang Biological achieving a "five consecutive limit-up" status, closing with over 290,000 sealed orders on the limit-up board [2][4] - Haiwang Biological's market capitalization reached 10.814 billion, with a trading volume ratio of 0.78 and a price increase of 9.89% [3] - The demand for cold medicine is expected to exceed market expectations due to a significant rise in flu cases, with the flu positivity rate nearing 45% nationally [8] Group 2 - The Fujian Free Trade Zone sector performed well, with stocks like Jiarong Technology and Haiwan Food hitting limit-up, contributing to a 51% increase in the sector since the beginning of the year [9][10] - Recent policies in Fujian aim to enhance digital economy competitiveness and promote the development of computing infrastructure, targeting a public computing scale of over 12 EFLOPS by the end of 2027 [12] - The Fujian provincial government is focusing on developing multiple trillion-yuan industrial clusters, including biomedicine and artificial intelligence, to strengthen the local economy [13]